LISSAMMA FRANCIS: Open Payments
NPI 1851938484 · WEST CALDWELL, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$713 in 26 payments from 7 companies in 2025. Trend: 2023 $981 · 2024 $408 · 2025 $713
Food & beverage: $713
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $425 |
| Otsuka America Pharmaceutical, Inc. | 7 | $118 |
| PFIZER INC. | 3 | $53 |
| ABBVIE INC. | 3 | $47 |
| Aimmune Therapeutics, Inc. | 2 | $34 |
| Lilly USA, LLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
Products named: CAPLYTA, REXULTI, PAXLOVID, VRAYLAR, ZENPEP, ZEPBOUND, AUSTEDO XR.
Industry payments across NJ — which companies pay providers there.
